+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Carbetocin Market by Indication, Formulation, Route Of Administration, End User, Distribution Channel - Global Forecast to 2030- Product Image
Carbetocin Market by Indication, Formulation, Route Of Administration, End User, Distribution Channel - Global Forecast to 2030- Product Image
Sale

Carbetocin Market by Indication, Formulation, Route Of Administration, End User, Distribution Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 198 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6010691
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The global carbetocin market is experiencing decisive transformation as advanced solutions reshape postpartum hemorrhage management, creating new opportunities for stakeholders to drive impact across clinical, operational, and commercial dimensions.

Market Snapshot: Carbetocin Market Growth and Trends

The carbetocin market grew from USD 211.76 million in 2024 to USD 224.63 million in 2025. It is expected to continue growing at a CAGR of 5.90%, reaching USD 298.85 million by 2030. This upward trajectory reflects heightened demand for effective postpartum hemorrhage therapies worldwide, reinforced by evolving standards in obstetric care, recent regulatory endorsements, and increased accessibility in established and emerging regions.

Scope & Segmentation

The scope of this report covers all key commercial and clinical segments, dissecting market dynamics for actionable insight into the evolving uterotonic therapy landscape.

  • Indications: Prevention of postpartum hemorrhage and treatment of postpartum hemorrhage, each relevant for both cesarean section and vaginal delivery contexts.
  • Formulation Types: Prefilled syringes and vials, catering to different healthcare settings and workflow priorities.
  • Routes of Administration: Intramuscular and intravenous, supporting varied clinical protocols and patient considerations.
  • End Users: Hospitals, birthing centers, and clinics, with adoption shaped by procurement capacities, staffing, and infrastructure.
  • Distribution Channels: Hospital pharmacies and retail pharmacies, each influencing product access and dispensing practices.
  • Regional Coverage: Americas (including United States, Canada, Mexico, Brazil, Argentina, and select US states), Europe, Middle East & Africa (spanning the UK, Germany, France, major Middle Eastern and African countries), and Asia-Pacific (including China, India, Japan, Australia, South Korea, and several Southeast Asian markets).
  • Key Companies Profiled: Ferring Pharmaceuticals, Fresenius Kabi AG, Gland Pharma Limited, Intas Pharmaceuticals Limited, Merck & Co., Inc., Pfizer Inc., Haffkine Bio-Pharmaceutical Corporation Limited, Cipla Limited, Sun Pharmaceutical Industries Limited, and Zhejiang Jingxin Pharmaceutical Co., Ltd. [ImageId=GUID]

Key Takeaways for Senior Decision-Makers

  • Carbetocin has transitioned from being a niche agent to an integral component of postpartum hemorrhage management, driven by clinical efficacy and flexible storage requirements, making it suitable for a wide range of care settings.
  • Leading medical associations and evolving clinical guidelines are accelerating the adoption of carbetocin, with a notable shift toward standardization and integration into routine obstetric protocols.
  • Pharmaceutical manufacturers are enhancing production scalability and exploring innovations such as heat-stable formulations and advanced delivery mechanisms, supporting differentiated product positioning and expanding global reach.
  • Strategic collaborations—including alliances for supply chain optimization, licensing, and knowledge transfer—are enabling both established firms and agile biotechs to navigate market complexities and respond to localized needs.
  • Competitive advantage is increasingly defined by the ability to ensure product availability, operational resilience, and alignment with regional policy environments amidst fluctuating regulatory and reimbursement landscapes.

Tariff Impact and US Market Adjustments

New import duties imposed in 2025 have recalibrated procurement, pricing, and manufacturing strategies in the US carbetocin market. Stakeholders are responding by leveraging offshore production, seeking optimal tariff classifications, and restructuring supply chains to minimize financial exposure. Large health systems and group purchasing organizations are using volume-based negotiations to buffer against increased costs, while secondary strategies such as local compounding and parallel imports are emerging to safeguard supply continuity.

Methodology & Data Sources

This report employs a multi-layered methodology combining secondary research from peer-reviewed journals, regulatory documents, and industry reports with primary interviews of key opinion leaders, supply chain specialists, and payers. Rigorous quantitative validation and scenario analyses ensure accuracy and transparency of findings.

Why This Carbetocin Market Report Matters

  • Equips decision-makers with segmented, actionable intelligence to support product development, regional entry, and operational risk management in the evolving carbetocin market.
  • Delivers clarity on regulatory trends, supply chain imperatives, and competitive positioning—critical for shaping strategic investments and anticipating market shifts.
  • Facilitates comparison of market access models across geographies, helping leaders optimize strategies for both mature and emerging healthcare systems.

Conclusion

The carbetocin market is positioned for sustained growth, underpinned by evidence-driven adoption, supply chain innovation, and adaptive strategies for global expansion. This report enables leaders to navigate complexity and seize strategic opportunities in maternal health.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Carbetocin Market, by Indication
8.1. Introduction
8.2. Prevention Of Postpartum Hemorrhage
8.2.1. Cesarean Section
8.2.2. Vaginal Delivery
8.3. Treatment Of Postpartum Hemorrhage
8.3.1. Cesarean Section
8.3.2. Vaginal Delivery
9. Carbetocin Market, by Formulation
9.1. Introduction
9.2. Prefilled Syringe
9.3. Vial
10. Carbetocin Market, by Route Of Administration
10.1. Introduction
10.2. Intramuscular
10.3. Intravenous
11. Carbetocin Market, by End User
11.1. Introduction
11.2. Birthing Centers
11.3. Clinics
11.4. Hospitals
12. Carbetocin Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacies
12.3. Retail Pharmacies
13. Americas Carbetocin Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Carbetocin Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Carbetocin Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Ferring Pharmaceuticals
16.3.2. Fresenius Kabi AG
16.3.3. Gland Pharma Limited
16.3.4. Intas Pharmaceuticals Limited
16.3.5. Merck & Co., Inc.
16.3.6. Pfizer Inc.
16.3.7. Haffkine Bio-Pharmaceutical Corporation Limited
16.3.8. Cipla Limited
16.3.9. Sun Pharmaceutical Industries Limited
16.3.10. Zhejiang Jingxin Pharmaceutical Co., Ltd.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. CARBETOCIN MARKET MULTI-CURRENCY
FIGURE 2. CARBETOCIN MARKET MULTI-LANGUAGE
FIGURE 3. CARBETOCIN MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL CARBETOCIN MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL CARBETOCIN MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CARBETOCIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CARBETOCIN MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CARBETOCIN MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CARBETOCIN MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CARBETOCIN MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CARBETOCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CARBETOCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CARBETOCIN MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL CARBETOCIN MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL CARBETOCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL CARBETOCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS CARBETOCIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS CARBETOCIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES CARBETOCIN MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES CARBETOCIN MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CARBETOCIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CARBETOCIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC CARBETOCIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC CARBETOCIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. CARBETOCIN MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. CARBETOCIN MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. CARBETOCIN MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CARBETOCIN MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CARBETOCIN MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CARBETOCIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL CARBETOCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL CARBETOCIN MARKET SIZE, BY PREVENTION OF POSTPARTUM HEMORRHAGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CARBETOCIN MARKET SIZE, BY CESAREAN SECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CARBETOCIN MARKET SIZE, BY VAGINAL DELIVERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CARBETOCIN MARKET SIZE, BY PREVENTION OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CARBETOCIN MARKET SIZE, BY TREATMENT OF POSTPARTUM HEMORRHAGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CARBETOCIN MARKET SIZE, BY CESAREAN SECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CARBETOCIN MARKET SIZE, BY VAGINAL DELIVERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CARBETOCIN MARKET SIZE, BY TREATMENT OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CARBETOCIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CARBETOCIN MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CARBETOCIN MARKET SIZE, BY VIAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CARBETOCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CARBETOCIN MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CARBETOCIN MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CARBETOCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CARBETOCIN MARKET SIZE, BY BIRTHING CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CARBETOCIN MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CARBETOCIN MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CARBETOCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL CARBETOCIN MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL CARBETOCIN MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS CARBETOCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS CARBETOCIN MARKET SIZE, BY PREVENTION OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS CARBETOCIN MARKET SIZE, BY TREATMENT OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS CARBETOCIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS CARBETOCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS CARBETOCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS CARBETOCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS CARBETOCIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 36. UNITED STATES CARBETOCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 37. UNITED STATES CARBETOCIN MARKET SIZE, BY PREVENTION OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 38. UNITED STATES CARBETOCIN MARKET SIZE, BY TREATMENT OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 39. UNITED STATES CARBETOCIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 40. UNITED STATES CARBETOCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 41. UNITED STATES CARBETOCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES CARBETOCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES CARBETOCIN MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 44. CANADA CARBETOCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 45. CANADA CARBETOCIN MARKET SIZE, BY PREVENTION OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 46. CANADA CARBETOCIN MARKET SIZE, BY TREATMENT OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 47. CANADA CARBETOCIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 48. CANADA CARBETOCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 49. CANADA CARBETOCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 50. CANADA CARBETOCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 51. MEXICO CARBETOCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 52. MEXICO CARBETOCIN MARKET SIZE, BY PREVENTION OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 53. MEXICO CARBETOCIN MARKET SIZE, BY TREATMENT OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 54. MEXICO CARBETOCIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 55. MEXICO CARBETOCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 56. MEXICO CARBETOCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 57. MEXICO CARBETOCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 58. BRAZIL CARBETOCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 59. BRAZIL CARBETOCIN MARKET SIZE, BY PREVENTION OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 60. BRAZIL CARBETOCIN MARKET SIZE, BY TREATMENT OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 61. BRAZIL CARBETOCIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 62. BRAZIL CARBETOCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 63. BRAZIL CARBETOCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 64. BRAZIL CARBETOCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 65. ARGENTINA CARBETOCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 66. ARGENTINA CARBETOCIN MARKET SIZE, BY PREVENTION OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 67. ARGENTINA CARBETOCIN MARKET SIZE, BY TREATMENT OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 68. ARGENTINA CARBETOCIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 69. ARGENTINA CARBETOCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA CARBETOCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA CARBETOCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 72. EUROPE, MIDDLE EAST & AFRICA CARBETOCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 73. EUROPE, MIDDLE EAST & AFRICA CARBETOCIN MARKET SIZE, BY PREVENTION OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 74. EUROPE, MIDDLE EAST & AFRICA CARBETOCIN MARKET SIZE, BY TREATMENT OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 75. EUROPE, MIDDLE EAST & AFRICA CARBETOCIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 76. EUROPE, MIDDLE EAST & AFRICA CARBETOCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 77. EUROPE, MIDDLE EAST & AFRICA CARBETOCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA CARBETOCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA CARBETOCIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 80. UNITED KINGDOM CARBETOCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 81. UNITED KINGDOM CARBETOCIN MARKET SIZE, BY PREVENTION OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 82. UNITED KINGDOM CARBETOCIN MARKET SIZE, BY TREATMENT OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 83. UNITED KINGDOM CARBETOCIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 84. UNITED KINGDOM CARBETOCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 85. UNITED KINGDOM CARBETOCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 86. UNITED KINGDOM CARBETOCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 87. GERMANY CARBETOCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 88. GERMANY CARBETOCIN MARKET SIZE, BY PREVENTION OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 89. GERMANY CARBETOCIN MARKET SIZE, BY TREATMENT OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 90. GERMANY CARBETOCIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 91. GERMANY CARBETOCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 92. GERMANY CARBETOCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 93. GERMANY CARBETOCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 94. FRANCE CARBETOCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 95. FRANCE CARBETOCIN MARKET SIZE, BY PREVENTION OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 96. FRANCE CARBETOCIN MARKET SIZE, BY TREATMENT OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 97. FRANCE CARBETOCIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 98. FRANCE CARBETOCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 99. FRANCE CARBETOCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 100. FRANCE CARBETOCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 101. RUSSIA CARBETOCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 102. RUSSIA CARBETOCIN MARKET SIZE, BY PREVENTION OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 103. RUSSIA CARBETOCIN MARKET SIZE, BY TREATMENT OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 104. RUSSIA CARBETOCIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 105. RUSSIA CARBETOCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 106. RUSSIA CARBETOCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 107. RUSSIA CARBETOCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 108. ITALY CARBETOCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 109. ITALY CARBETOCIN MARKET SIZE, BY PREVENTION OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 110. ITALY CARBETOCIN MARKET SIZE, BY TREATMENT OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 111. ITALY CARBETOCIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 112. ITALY CARBETOCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 113. ITALY CARBETOCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 114. ITALY CARBETOCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 115. SPAIN CARBETOCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 116. SPAIN CARBETOCIN MARKET SIZE, BY PREVENTION OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 117. SPAIN CARBETOCIN MARKET SIZE, BY TREATMENT OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 118. SPAIN CARBETOCIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 119. SPAIN CARBETOCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 120. SPAIN CARBETOCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 121. SPAIN CARBETOCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 122. UNITED ARAB EMIRATES CARBETOCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 123. UNITED ARAB EMIRATES CARBETOCIN MARKET SIZE, BY PREVENTION OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 124. UNITED ARAB EMIRATES CARBETOCIN MARKET SIZE, BY TREATMENT OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 125. UNITED ARAB EMIRATES CARBETOCIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 126. UNITED ARAB EMIRATES CARBETOCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 127. UNITED ARAB EMIRATES CARBETOCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 128. UNITED ARAB EMIRATES CARBETOCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 129. SAUDI ARABIA CARBETOCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 130. SAUDI ARABIA CARBETOCIN MARKET SIZE, BY PREVENTION OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 131. SAUDI ARABIA CARBETOCIN MARKET SIZE, BY TREATMENT OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 132. SAUDI ARABIA CARBETOCIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 133. SAUDI ARABIA CARBETOCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 134. SAUDI ARABIA CARBETOCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 135. SAUDI ARABIA CARBETOCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 136. SOUTH AFRICA CARBETOCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 137. SOUTH AFRICA CARBETOCIN MARKET SIZE, BY PREVENTION OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 138. SOUTH AFRICA CARBETOCIN MARKET SIZE, BY TREATMENT OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 139. SOUTH AFRICA CARBETOCIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 140. SOUTH AFRICA CARBETOCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 141. SOUTH AFRICA CARBETOCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 142. SOUTH AFRICA CARBETOCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 143. DENMARK CARBETOCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 144. DENMARK CARBETOCIN MARKET SIZE, BY PREVENTION OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 145. DENMARK CARBETOCIN MARKET SIZE, BY TREATMENT OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 146. DENMARK CARBETOCIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 147. DENMARK CARBETOCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 148. DENMARK CARBETOCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 149. DENMARK CARBETOCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 150. NETHERLANDS CARBETOCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 151. NETHERLANDS CARBETOCIN MARKET SIZE, BY PREVENTION OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 152. NETHERLANDS CARBETOCIN MARKET SIZE, BY TREATMENT OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 153. NETHERLANDS CARBETOCIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 154. NETHERLANDS CARBETOCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 155. NETHERLANDS CARBETOCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 156. NETHERLANDS CARBETOCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 157. QATAR CARBETOCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 158. QATAR CARBETOCIN MARKET SIZE, BY PREVENTION OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 159. QATAR CARBETOCIN MARKET SIZE, BY TREATMENT OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 160. QATAR CARBETOCIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 161. QATAR CARBETOCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 162. QATAR CARBETOCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 163. QATAR CARBETOCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 164. FINLAND CARBETOCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 165. FINLAND CARBETOCIN MARKET SIZE, BY PREVENTION OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 166. FINLAND CARBETOCIN MARKET SIZE, BY TREATMENT OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 167. FINLAND CARBETOCIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 168. FINLAND CARBETOCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 169. FINLAND CARBETOCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 170. FINLAND CARBETOCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 171. SWEDEN CARBETOCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 172. SWEDEN CARBETOCIN MARKET SIZE, BY PREVENTION OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 173. SWEDEN CARBETOCIN MARKET SIZE, BY TREATMENT OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 174. SWEDEN CARBETOCIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 175. SWEDEN CARBETOCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 176. SWEDEN CARBETOCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 177. SWEDEN CARBETOCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 178. NIGERIA CARBETOCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 179. NIGERIA CARBETOCIN MARKET SIZE, BY PREVENTION OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 180. NIGERIA CARBETOCIN MARKET SIZE, BY TREATMENT OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 181. NIGERIA CARBETOCIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 182. NIGERIA CARBETOCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 183. NIGERIA CARBETOCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 184. NIGERIA CARBETOCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 185. EGYPT CARBETOCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 186. EGYPT CARBETOCIN MARKET SIZE, BY PREVENTION OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 187. EGYPT CARBETOCIN MARKET SIZE, BY TREATMENT OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 188. EGYPT CARBETOCIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 189. EGYPT CARBETOCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 190. EGYPT CARBETOCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 191. EGYPT CARBETOCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 192. TURKEY CARBETOCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 193. TURKEY CARBETOCIN MARKET SIZE, BY PREVENTION OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 194. TURKEY CARBETOCIN MARKET SIZE, BY TREATMENT OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 195. TURKEY CARBETOCIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 196. TURKEY CARBETOCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 197. TURKEY CARBETOCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 198. TURKEY CARBETOCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 199. ISRAEL CARBETOCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 200. ISRAEL CARBETOCIN MARKET SIZE, BY PREVENTION OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 201. ISRAEL CARBETOCIN MARKET SIZE, BY TREATMENT OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 202. ISRAEL CARBETOCIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 203. ISRAEL CARBETOCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 204. ISRAEL CARBETOCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 205. ISRAEL CARBETOCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 206. NORWAY CARBETOCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 207. NORWAY CARBETOCIN MARKET SIZE, BY PREVENTION OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 208. NORWAY CARBETOCIN MARKET SIZE, BY TREATMENT OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 209. NORWAY CARBETOCIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 210. NORWAY CARBETOCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 211. NORWAY CARBETOCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 212. NORWAY CARBETOCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 213. POLAND CARBETOCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 214. POLAND CARBETOCIN MARKET SIZE, BY PREVENTION OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 215. POLAND CARBETOCIN MARKET SIZE, BY TREATMENT OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 216. POLAND CARBETOCIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 217. POLAND CARBETOCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 218. POLAND CARBETOCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 219. POLAND CARBETOCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 220. SWITZERLAND CARBETOCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 221. SWITZERLAND CARBETOCIN MARKET SIZE, BY PREVENTION OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 222. SWITZERLAND CARBETOCIN MARKET SIZE, BY TREATMENT OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 223. SWITZERLAND CARBETOCIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 224. SWITZERLAND CARBETOCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 225. SWITZERLAND CARBETOCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 226. SWITZERLAND CARBETOCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 227. ASIA-PACIFIC CARBETOCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 228. ASIA-PACIFIC CARBETOCIN MARKET SIZE, BY PREVENTION OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 229. ASIA-PACIFIC CARBETOCIN MARKET SIZE, BY TREATMENT OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 230. ASIA-PACIFIC CARBETOCIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 231. ASIA-PACIFIC CARBETOCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 232. ASIA-PACIFIC CARBETOCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 233. ASIA-PACIFIC CARBETOCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 234. ASIA-PACIFIC CARBETOCIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 235. CHINA CARBETOCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 236. CHINA CARBETOCIN MARKET SIZE, BY PREVENTION OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 237. CHINA CARBETOCIN MARKET SIZE, BY TREATMENT OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 238. CHINA CARBETOCIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 239. CHINA CARBETOCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 240. CHINA CARBETOCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 241. CHINA CARBETOCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 242. INDIA CARBETOCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 243. INDIA CARBETOCIN MARKET SIZE, BY PREVENTION OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 244. INDIA CARBETOCIN MARKET SIZE, BY TREATMENT OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 245. INDIA CARBETOCIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 246. INDIA CARBETOCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 247. INDIA CARBETOCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 248. INDIA CARBETOCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 249. JAPAN CARBETOCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 250. JAPAN CARBETOCIN MARKET SIZE, BY PREVENTION OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 251. JAPAN CARBETOCIN MARKET SIZE, BY TREATMENT OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 252. JAPAN CARBETOCIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 253. JAPAN CARBETOCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 254. JAPAN CARBETOCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 255. JAPAN CARBETOCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 256. AUSTRALIA CARBETOCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 257. AUSTRALIA CARBETOCIN MARKET SIZE, BY PREVENTION OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 258. AUSTRALIA CARBETOCIN MARKET SIZE, BY TREATMENT OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 259. AUSTRALIA CARBETOCIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 260. AUSTRALIA CARBETOCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 261. AUSTRALIA CARBETOCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 262. AUSTRALIA CARBETOCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 263. SOUTH KOREA CARBETOCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 264. SOUTH KOREA CARBETOCIN MARKET SIZE, BY PREVENTION OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 265. SOUTH KOREA CARBETOCIN MARKET SIZE, BY TREATMENT OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 266. SOUTH KOREA CARBETOCIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 267. SOUTH KOREA CARBETOCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 268. SOUTH KOREA CARBETOCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 269. SOUTH KOREA CARBETOCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 270. INDONESIA CARBETOCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 271. INDONESIA CARBETOCIN MARKET SIZE, BY PREVENTION OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 272. INDONESIA CARBETOCIN MARKET SIZE, BY TREATMENT OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 273. INDONESIA CARBETOCIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 274. INDONESIA CARBETOCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 275. INDONESIA CARBETOCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 276. INDONESIA CARBETOCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 277. THAILAND CARBETOCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 278. THAILAND CARBETOCIN MARKET SIZE, BY PREVENTION OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 279. THAILAND CARBETOCIN MARKET SIZE, BY TREATMENT OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 280. THAILAND CARBETOCIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 281. THAILAND CARBETOCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 282. THAILAND CARBETOCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 283. THAILAND CARBETOCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 284. PHILIPPINES CARBETOCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 285. PHILIPPINES CARBETOCIN MARKET SIZE, BY PREVENTION OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 286. PHILIPPINES CARBETOCIN MARKET SIZE, BY TREATMENT OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 287. PHILIPPINES CARBETOCIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 288. PHILIPPINES CARBETOCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 289. PHILIPPINES CARBETOCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 290. PHILIPPINES CARBETOCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 291. MALAYSIA CARBETOCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 292. MALAYSIA CARBETOCIN MARKET SIZE, BY PREVENTION OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 293. MALAYSIA CARBETOCIN MARKET SIZE, BY TREATMENT OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 294. MALAYSIA CARBETOCIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 295. MALAYSIA CARBETOCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 296. MALAYSIA CARBETOCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 297. MALAYSIA CARBETOCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 298. SINGAPORE CARBETOCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 299. SINGAPORE CARBETOCIN MARKET SIZE, BY PREVENTION OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 300. SINGAPORE CARBETOCIN MARKET SIZE, BY TREATMENT OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 301. SINGAPORE CARBETOCIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 302. SINGAPORE CARBETOCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 303. SINGAPORE CARBETOCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 304. SINGAPORE CARBETOCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 305. VIETNAM CARBETOCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 306. VIETNAM CARBETOCIN MARKET SIZE, BY PREVENTION OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 307. VIETNAM CARBETOCIN MARKET SIZE, BY TREATMENT OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 308. VIETNAM CARBETOCIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 309. VIETNAM CARBETOCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 310. VIETNAM CARBETOCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 311. VIETNAM CARBETOCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 312. TAIWAN CARBETOCIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 313. TAIWAN CARBETOCIN MARKET SIZE, BY PREVENTION OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 314. TAIWAN CARBETOCIN MARKET SIZE, BY TREATMENT OF POSTPARTUM HEMORRHAGE, 2018-2030 (USD MILLION)
TABLE 315. TAIWAN CARBETOCIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 316. TAIWAN CARBETOCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 317. TAIWAN CARBETOCIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 318. TAIWAN CARBETOCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 319. CARBETOCIN MARKET SHARE, BY KEY PLAYER, 2024
TABLE 320. CARBETOCIN MARKET, FPNV POSITIONING MATRIX, 2024

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Carbetocin market report include:
  • Ferring Pharmaceuticals
  • Fresenius Kabi AG
  • Gland Pharma Limited
  • Intas Pharmaceuticals Limited
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Haffkine Bio-Pharmaceutical Corporation Limited
  • Cipla Limited
  • Sun Pharmaceutical Industries Limited
  • Zhejiang Jingxin Pharmaceutical Co., Ltd.

Table Information

Report AttributeDetails
No. of Pages198
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 224.63 Million
Forecasted Market Value ( USD ) by 2030 $ 298.85 Million
Compound Annual Growth Rate5.9%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Carboprost Tromethamine - Global Strategic Business Report - Product Image

Carboprost Tromethamine - Global Strategic Business Report

  • Report
  • 276 Pages
  • Global
From
Carboprost Tromethamine Market Report 2025 - Product Image

Carboprost Tromethamine Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Dydrogesterone Market by Form, Route of Administration, Product Type, Distribution Channel, Indication, Dosage Strength - Global Forecast to 2030 - Product Image

Dydrogesterone Market by Form, Route of Administration, Product Type, Distribution Channel, Indication, Dosage Strength - Global Forecast to 2030

  • Report
  • 188 Pages
  • Global
From
Genital Herpes Treatment Market by Molecule, Therapy Model, Distribution Channel, Route of Administration, End User, Indication - Global Forecast to 2030 - Product Image

Genital Herpes Treatment Market by Molecule, Therapy Model, Distribution Channel, Route of Administration, End User, Indication - Global Forecast to 2030

  • Report
  • 182 Pages
  • Global
From
Preeclampsia - Market Insight, Epidemiology, and Market Forecast - 2034 - Product Image

Preeclampsia - Market Insight, Epidemiology, and Market Forecast - 2034

  • Report
  • 124 Pages
  • Global
From

About the Carbetocin Market

Carbetocin is a synthetic oxytocin analogue used in the treatment of postpartum haemorrhage (PPH). It is a drug used in the field of Sexual and Reproductive Health (SRH) and is administered intravenously or intramuscularly. Carbetocin is used to reduce the risk of PPH, a major cause of maternal mortality and morbidity. It is also used to reduce the need for additional uterotonics and to reduce the risk of uterine atony. Carbetocin has been shown to be more effective than oxytocin in preventing PPH and has fewer side effects. Carbetocin is available in many countries, including the United States, Canada, Australia, and the United Kingdom. It is approved for use in the treatment of PPH in the United States and Canada. Some companies in the Carbetocin market include Ferring Pharmaceuticals, Pfizer, Merck, and Novartis. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.